Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 2 Bulls In A China Shop Podcast - Bonus Episode with Dan Leg
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(59)
•••
Post by Fotoforesteron May 20, 2021 10:45pm
218 Views
Post# 33246082

2 Bulls In A China Shop Podcast - Bonus Episode with Dan Leg

2 Bulls In A China Shop Podcast - Bonus Episode with Dan Leg
Hey in case you folks aren't on Stocktwits the "2 Bulls in a China Shop Podcast" will be hosting a bonus episode with our CEO Dan Legault and it sounds like they are looking for questions. It sure seems like a great opportunity to put forward any questions or concerns you might have. I listened to a couple episodes of theirs today and I enjoyed them and will probably continue to listen in. They're pretty good hosts which is exciting - it'll be interesting to see Dan in a more casual setting too and also good to see Dan doing something for us Retail apes. Should be fun if it's not the usual spiel. Kyle from Stocktwits (one of the hosts) can be reached here: https://stocktwits.com/Kyle003p the email link for the podcast itself: 2bulls@financialineptitude.com
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities